CAV1 and metabolic disease: Our transgenic zebrafish and knockout mice, combined with a innovative approach to assay enterocyte endocytosis in vivo, allows for an unprecedented understanding of enterocyte CAV1 cell biology, the effects of enterocyte CAV1 on systemic lipid metabolism, and how CAV1 in the intestinal epithelia influence metabolic disease risk through alterations in circulating lipids.